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Summary 
 
Cancer is one of the leading causes of death in persons aged 1 to 14 years and leukemias are 
the most common malignancies in childhood and are the primary cause of cancer-related 
mortality in the world. Chemotherapy is quite effective in treating cancers, but after 
successful treatment, young female cancer survivors face a potential threat of premature 
ovarian failure (POF) and infertility from gonadotoxicity of chemotherapeutic agent. 
Cytostatic drugs can target the oocyte directly, or can induce oocyte death indirectly via 
damage to surrounding granulosa cells, which play a key role in folliculogenesis and oocyte 
maturation. A more thorough understanding of the mechanism behind chemotherapy-induced 
infertility is necessary to develop new methods to preserve fertility in these patients. 
MicroRNAs (miRNAs) have recently begun to be explored in ovarian cells as small 
molecules with critical regulatory role. Importantly, the miRNAs profile in granulosa cells 
may possess high potential as a new marker for successful folliculogenesis and oocyte 
development. They can control steroidogenesis in cultured granulosa cells and are involved in 
control of proliferation, apoptosis and carcinogenesis. MicroRNA-21 (miR-21) and 
microRNA-132 (miR-132) are of the most abundant and highly expressed miRNAs in human 
oocytes and granulosa cells. miR-21 is an oncogenic miRNA and plays a critical role in 
maintaining the survival of granulosa cells in periovulatory follicles and acts as an 
antiapoptotic factor in granulosa cells. miR-132 has a key role in promotion of estradiol (E2) 
synthesis in murine ovarian granulosa cells.  
The present study aimed to determine in vitro the potential association of different 
chemotherapeutic agents as part of childhood cancer treatment with infertility in adults who 
survived pediatric cancer and to explore effects of chemotherapeutic agents on expression of 
two important miRNAs (miR-21 and miR-132) in granulosa cells. The concentration-
dependent cytotoxicity of doxorubicin (DOX), vincristine (VCR), methotrexate (MTX) and 
cyclophosphamide (CYC) has been assessed against isolated granulosa cells from women 
receiving assisted reproduction treatment and human granulosa cell lines (KGN and COV434) 
in comparison to human leukemia T cell line Jurkat. The granulosa cells  were cultured for 72 
h and then incubated with different doses of doxorubicin (0.01, 0.05, 0.1, 0.2 and 0.5 μg/ml), 
vincristine (0.01, 0.1, 1, 5 and 10 μg/ml), methotrexate (0.1, 1, 5, 10 and 50 μg/ml) or 
cyclophosphamide (1, 5, 10, 50 and 100 μg/ml) for 48 h. Simultaneously, the granulosa cell 
lines (KGN and COV434) and Jurkat cells were treated for 12, 24 and 48 h with the same 
doses of doxorubicin, vincristine, methotrexate or cyclophosphamide. Subsequently, cell 
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viability was evaluated by MTS assay and apoptosis by annexin V and propidium iodide 
staining in flow cytometry and the concentrations of estradiol in culture supernatants by 
immunoassay. Effects of chemotherapeutic agents on expression miR-21 and miR-132 in 
primary granulosa cells and cell lines as well as in Jurkat cells were assessed by using 
quantitative real time-PCR.  
The results showed that the drugs induced time- and concentration-dependent inhibitory 
effects on the proliferation of primary granulosa cells and cell lines and different levels of 
apoptosis. Cyclophosphamide and doxorubicin exerted a similar degree of cytotoxicty on 
primary granulosa cells and resulted in significant decrease in cell viability, increased cell 
death and decreased estradiol concentration linearly. Treatment with methotrexate induced 
cell death in Jurkat cells, while the magnitude of this response in primary granulosa cells was 
significantly less pronounced. Vincristine had the highest cytotoxic effect on viability of 
Jurkat, KGN and COV434 cells. Interestingly, doxorubicin induced overexpression of miR-21 
in COV434 and miR-132 in KGN and Jurkat cells. 
In conclusion, these findings demonstrate the extremely damaging effects of 
cyclophosphamide and doxorubicin on granulosa cells and the comparatively low influence of 
methotrexate and vincristine on the viability and steroidogenesis of human primary granulosa 
cells. This may suggest, at similar anti-leukemia efficacy of the compared drugs, that 
methotrexate and vincristine induce lower ovarian and reproductive toxicity. This study may 
provide novel information on the effects of doxorubicin on expression of miR-21 and miR-
132 which may bring benefits to reproductive medicine. 
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Zusammenfassung  
Die Erkrankung Krebs stellt eine häufigste Todesursache bei Personen im Alter von 1 bis 14 
Jahren dar. Die Leukämie zählt hierbei als die häufigste Krebserkrankung im Kindesalter und 
gilt darüber hinaus als weltweit primäre Ursache der Krebsmortalität. Zur  Behandlung von 
infantilen Krebserkrankungen wird die Chemotherapie als effektive Option eingestuft, welche 
jedoch das Risiko birgt, dass nach erfolgreicher Behandlung junge weibliche 
Krebsüberlebende aufgrund der Gonadotoxizität von Chemotherapeutika vorzeitig von 
Ovarialinsuffizienz (POF) sowie Infertilität betroffen sind. Viele Zytostatika richten sich 
direkt auf die Oozyte oder können den Oozytentod indirekt durch Schädigung der 
umgebenden Granulosazellen induzieren, welche eine Schlüsselrolle für die Follikulogenese 
und die Oozytenreifung spielen. Ein gründlicheres Verständnis des Mechanismus der 
Chemotherapie-induzierten Infertilität ist notwendig, um neue Methoden zur Erhaltung der 
Fertilität dieser Patienten zu entwickeln. 
In den vergangenen Jahren wurden mikroRNAs (miRNAs) als kleine Moleküle mit 
bedeutender regulatorischer Rolle in Ovarialzellen eingestuft. Dabei besitzt das miRNA-Profil 
in Granulosazellen ein hohes Potential, als diagnostischer Marker für eine erfolgreiche 
Follikel- und Oozytenentwicklung genutzt werden zu können. MiRNAs können die 
Steroidogenese in kultivierten Granulosazellen kontrollieren und beeinflussen regulatorische 
Prozesse wie Proliferation, Apoptose und Karzinogenese. miRNA-21 (miR-21) und miRNA-
132 (miR-132) sind die am stärksten exprimierten miRNAs in menschlichen Oozyten und 
Granulosazellen. Die onkogene miR-21 spielt eine wichtige Rolle bei der Aufrechterhaltung 
des Überlebens von Granulosazellen in periovulatorischen Follikeln und wirkt als anti-
apoptotischer Faktor in Granulosazellen. miR-132 besitzt eine Schlüsselrolle bei der 
Förderung der Östradiol-Synthese in murinen Ovarialgranulosazellen. 
Ziel der vorliegenden Studie war es, den möglichen Zusammenhang zwischen der einer 
erfolgten Chemotherapie im Kindesalter und einer verstärkt auftretenden Infertilität bei 
jungen Erwachsenen, die pädiatrische Krebserkrankungen überlebt haben, in vitro zu 
untersuchen. Des Weiteren sollte der Einfluss dieser Chemotherapeutika auf die Expression 
von zwei für die Regulation von Granulosazellen wichtigen miRNAs (miR-21 und miR-132) 
erforscht werden. Die konzentrationsabhängige Zytotoxizität von Doxorubicin (DOX), 
Vincristin (VCR), Methotrexat (MTX) und Cyclophosphamid (CYC) auf primäre 
Granulosazellen, isoliert von der Follikelflüssigkeit von IVF-Patientinnen sowie auf zwei 
etablierte humane Granulosazelllinien (KGN und COV434) wurde analysiert und mit den 
Untersuchungen zytostatischer Wirkungen auf die humane leukämische T-Zelllinie Jurkat 
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gegenübergestellt. Dazu wurden die Granulosazellen für 72 h kultiviert und anschließend mit 
Doxorubicin (0,01, 0,05, 0,1, 0,2 und 0,5 μg/ml), Vincristin (0,01, 0,1, 1, 5 und 10 μg/ml), 
Methotrexat (0,1, 1, 5, 10 und 50 μg/ml) oder Cyclophosphamid (1, 5, 10, 50 und 100 μg/ml) 
in 5 verschiedenen Konzentrationen für 48 Stunden inkubiert. Die beiden Granulosazelllinien 
(KGN und COV434) sowie die Jurkat-Zellen wurden ebenfalls für 12, 24 und 48 h mit 
denselben Dosen von Doxorubicin, Vincristin, Methotrexat oder Cyclophosphamid behandelt. 
Anschließend wurde die Zellvitalität mittels MTS-Assay bestimmt, während der Anteil an 
apoptotischen Zellen durch die Annexin-V-und Propidiumiodid-Färbung via 
Durchflusszytometrie bewertet wurde. Gleichzeitig wurde die Konzentrationen von Östradiol 
in Kulturüberständen durch Immunoassays ermittelt. Die Effekte der Chemotherapeutika auf 
die Expression von miR-21 und miR-132 in primären Granulosazellen, den Granulosa-
Zelllinien sowie in Jurkat-Zellen wurde mittels quantitativer real time-PCR untersucht. 
Die Ergebnisse zeigten, dass die untersuchten Medikamente Zeit- und 
konzentrationsabhängige inhibitorische Effekte auf die Proliferation von primären 
Granulosazellen und die beiden Granulosa-Zelllinien hervorrufen und verschiedene 
Apoptoseraten induzieren. Cyclophosphamid und Doxorubicin wirkten auf primäre 
Granulosazellen ähnlich zytotoxisch, führten zu einer signifikanten Abnahme der Zell 
viabilität, einem erhöhten Zelltod und einer linear abnehmenden Östradiolkonzentration. Die 
Behandlung mit Methotrexat induzierte den nahezu vollständigen Zelltod in Jurkat-Zellen, 
während in primären Granulosazellen signifikant weniger Zellen apoptotisch reagierten. 
Vincristin zeigte die höchste zytotoxische Wirkung auf die Zellviabilität von Jurkat, KGN und 
COV434 Zellen. Interessanterweise induzierte Doxorubicin eine Überexpression von miR-21 
in COV434 und miR-132 in KGN und Jurkat-Zellen. 
Zusammenfassend zeigten diese Untersuchungen die äußerst schädigende Wirkungen von 
Cyclophosphamid und Doxorubicin auf die Granulosazellen und einen vergleichsweise 
geringen Einfluss von Methotrexat und Vincristin auf die Zellviabilität und Steroidogenese 
der humanen primären Granulosazellen. Dies kann bei einem zugleich ähnlichen anti-
leukämischen Effekt der untersuchten Medikamente nahelegen, dass Methotrexat und 
Vincristin die geringste Eierstock- und Reproduktionstoxizität induzieren. Zugleich konnten 
neue Erkenntnisse über die Wirkung von Doxorubicin auf die Expression von miR-21 und 
miR-132 generiert werden, was für den Bereich der reproduktiven Medizin in Zukunft genutzt 
werden könnte. 
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CHAPTER 1 INTRODUCTION 
1. Overview of the ovary
The mammalian ovary is a complex organ and has a variety of functions essential to the 
reproductive process. The human ovary by birth contains a fixed number of germ cells 
(oocytes) within primordial follicles, a basic functional unit which consists of an immature 
oocyte in meiotic arrest, enclosed by a small number of flattened pregranulosa cells. The 
primordial follicles constitute the resting pool of female germ cells required for the 
reproductive lifespan of the female (Edson et al. 2009). At around five months of gestational 
age, the human ovary establishes several million primordial follicles which are followed by a 
decline to approximately 1-2 million at the time of birth, about 300,000 at puberty and 
approximately 1,000 at an average age of 50–51 years, defined as the onset of the menopause. 
In the normal human reproductive life span, there are around 450 menstrual cycles. In each 
cycle small cohorts of primordial follicles are recruited out of the resting primordial pool and 
are activated to grow (Wallace and Kelsey 2010). Abnormalities in primordial follicle 
development lead to a number of pathophysiologies like premature ovarian failure and female 
infertility (Skinner 2005).  
1.1. Formation of ovarian follicle 
The ovarian follicle is the basic functional unit in the ovary that is composed of a developing 
oocyte and somatic cells. The granulosa cells and theca cells are the two primary somatic cell 
types in the ovarian follicle (Edson et al. 2009). Follicle formation is a process that known as 
germ cell nest breakdown. During fetal development, primordial germ cells (oocyte 
precursors) migrate from the yolk sac to the genital ridge where the undifferentiated gonad 
resides (Tingen et al. 2009). These germ cells (oogonia) massively proliferate by mitosis and 
develop in clusters or nests in which oogonia surrounded by squamous pre-granulosa cells 
(Gondos 1973). When germ cell nest formation is complete, mitosis of oogonia is ceased and 
meiosis starts. It is here that the oogonia become oocytes; thereafter these oocytes are arrested 
in prophase I of meiosis (Borum 1961).  
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1.2. Folliculogenesis 
Development and maturation of follicles to ovulation of the oocyte for subsequent 
fertilization, a process termed folliculogenesis, is one of the primary functions of the ovary 
(Edson et al. 2009). After puberty and through an unknown selection mechanism, small 
cohorts of primordial follicles are recruited out of the resting pool to undergo growth and 
differentiation (McGee and Hsueh 2000). However, normally only one follicle fully matures, 
and the rest undergo atresia, which is follicular programmed cell death via apoptosis. Once 
activated, the surrounding granulosa cells of these primordial follicles change from a flat to a 
cuboidal structure, marking the beginning of the primary follicle (Fig. 1). In the primary 
follicle, the oocyte grows and granulosa cells proliferate and form multiple layers of somatic 
cells that surround the oocyte, resulting in the formation of a secondary (preantral) follicle. 
After formation of the secondary follicle, theca cells begin to appear and surround the 
granulosa cells by formation of a layer (Matsuda et al. 2012). Then fluid filled patches form in 
the granulosa cell layers within the follicle, which coalesces to form the early antral (or 
tertiary) follicle (Soyal et al. 2000). 
Follicles at this stage are gonadotropin-responsive and begin to synthesize sex steroid 
hormones, because of the presence of both granulosa and theca cells. Pituitary follicle 
stimulating hormone (FSH) stimulates the follicle for further growth (Fritz and Speroff 2011) 
and the antrum continues to enlarge by action of FSH, resulting in the formation of a 
preovulatory follicle. The oocyte within the preovulatory follicle is surrounded by cumulus 
cells and as the preovulatory follicle continues to mature and increase in size, due to an 
increased volume of follicular fluid, granulosa cells produce estradiol. Thereafter, the 
luteinizing hormone (LH) surges causing the follicle to ovulate (Kumar and Sait 2011). When 
the oocyte is released, granulosa and theca cells differentiate into luteinized cells, to form the 
corpus luteum (Georges et al. 2014). 
Introduction                7 
Figure 1. Ovarian folliculogenesis 
Folliculogenesis begins with the recruitment of primordial follicles from a reserve pool to become 
primary follicles. Granulosa cells proliferate and form multiple layers around the oocyte; theca cells 
form a layer around the follicle in secondary (preantral) follicles. (FSH) stimulates the follicle for 
further growth to form antral and subsequently to preovulatory follicle. After ovulation, the antral 
follicle differentiates into the corpus luteum, and the granulosa and theca cells become luteinized 
cells. Modified (Georges et al. 2014). 
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1.3. Ovarian granulosa cells 
The most important cell type in the ovary that function as the ovarian nurse cells is granulosa 
cells which support development of the oocyte physically and provide the required 
microenvironment. Granulosa cells are somatic cells surrounding closely the oocyte and 
actively differentiating cells (Edson et al. 2009). Proliferation and cellular differentiation of 
granulosa cells are critical aspects for normal follicular growth, ovulation and luteinisation. 
During folliculogenesis, granulosa cells undergo alteration in cellular differentiation. 
Numerous actions of hormones and growth factors are required for regulation of granulosa 
cell differentiation. In the early primordial follicle stage, cells are non-steroidogenic and 
independent on steroid hormone (Richards and Midgley 1976, Oktay et al. 1997). However, in 
developmental stages before ovulation, FSH stimulates granulosa cells to convert androgens 
(coming from the thecal cells) to estradiol via cytochrome P450 aromatase (Albertini et al. 
2001, Senthilkumaran et al. 2004). After ovulation, granulosa cells turn into granulosa lutein 
cells that produce progesterone. The progesterone may maintain a potential pregnancy. The 
biosynthesis of two important steroid hormones in ovary, estradiol and progesterone, is a 
primary function of the granulosa cells in human. Estradiol plays an important role in ovarian 
follicle development, oocyte maturation, endometrial proliferation and its dysregulation 
contributes to the development of polycystic ovary syndrome (PCOS) and premature ovarian 
failure (Drummond and Findlay 1999). Granulosa cell possess specific receptors for the 
gonadotropins FSH and LH (Richards und Midgley 1976), for growth factors such as insulin-
like growth factor (IGF) (Adashi 1998) and anti-Müllerian Hormone (AMH), a member of the 
transforming growth factor beta (TGF-b) superfamily of growth factors (Knight and Glister 
2006). 
Granulosa cells have an important role in keeping of oocyte quality, which is a key factor in 
female fertility. The bidirectional communication between oocyte and granulosa cells is 
essential and must be tightly coordinated. The oocyte interacts with the granulosa cells 
through gap junctions which are channels formed by connexin proteins. However, oocytes 
have a closely control their surrounding somatic cells and directing them to perform functions 
required for correct development of the oocyte. Oocyte secretes growth-differentiation factor 
9 (GDF9) and bone morphogenetic protein 15 (BMP15), as two important oocyte-secreted 
factors (OSFs) which are members of the TGF-b superfamily, which activate signalling 
pathways in granulosa cells to regulate key genes and cellular processes required for their 
differentiation. In turn, granulosa cells are responsible for promoting oocyte growth and 
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development through ovarian follicular microenvironment and maternal signals (Gilchrist et 
al. 2008). 
1.3.1. Heterogeneity of granulosa cells 
The granulosa cells differentiate to become two anatomically and functionally distinct 
populations upon antrum formation (Fig. 2) (Telfer et al. 1988). Cumulus granulosa cells 
surround the oocyte and are ovulated with it. Through gap junctions between cumulus cells 
and the oocyte, cumulus cells provide nutrition for the oocyte and influence oocyte 
development as well as keeping the oocyte in meiotic arrest (Eppig und Downs 1984, Khamsi 
et al. 2001). The mural granulosa cells, which line the follicle wall and border the theca cells 
and play a steroidogenic role, remain behind following ovulation and regress to form the 
corpus luteum. Additionally, cumulus granulosa cells are different from mural granulosa cells 
in their response to gonadotropins (Khamsi et al. 2001). 
Figure 2.  Heterogeneity of the granulosa cellsin a healthy Graafian follicle. 
The cumulus granulosa cells surround the oocyte and mural granulosa cells line the follicle. Modified 
(Erickson 2008). 
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1.4. Ovarian Steroidogenesis 
Another primary function of the ovary is steroidogenesis which is a tightly regulated and 
complex process that involves a number of enzymatic reactions in both the theca and 
granulosa cells (Fig. 3). Steroidogenesis can be described with the two cell/two gonadotropin 
model (Hillier et al. 1994). In the early antral follicle theca cells contain LH receptors and, 
after stimulation, cholesterol is converted to pregnenolone by action of cytochrome-P450 
cholesterol side-chain cleavage (CYP11A1) (Miller 1988, Hanukoglu 1992). The enzyme 
17α-hydroxylase-17,20-desmolase (CYP17A1) converts pregnenolone and progesterone to 
dehydroepiandrosterone (DHEA) and androstenedione, respectively. In contrast to theca cells, 
granulosa cells of the early antral follicle contain only FSH receptor, which are reliant on 
androstenedione produced by the surrounding thecal cells to produce estradiol by action of 
aromatase (Jamnongjit and Hammes 2006).  
Figure 3. Two-cell, two-gonadotropin model of regulation of estrogen synthesis in the human 
ovary. 
Theca cells produce androstenedione from cholesterol after LH stimulation. Androstenedione is then 
transported to the granulosa cells where it is aromatized to estrone and finally converted to estradiol 
after FSH stimulation. Modified (Doshi and Agarwal 2013). 
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2. Common childhood cancers
Childhood cancer is one of the leading causes of death by disease among children in the world 
and the number of reported new cancer cases is increasing every year. The most common 
types of cancer diagnosed in children are acute lymphoblastic leukemia ALL (26%), brain and 
central nervous system tumors (21%), neuroblastoma (7%) and non-Hodgkin lymphoma 
(NHL) (6%) (Fig. 4) (Ward et al. 2014). Currently, treatment of childhood cancer has become 
increasingly successful, where approximately 80% of all patients diagnosed before 15 years of 
age will survive for 5 years (Keegan et al. 2016). The current number of survivors within 
Europe is unknown but is estimated to be between 300,000–500,000, which in Western 
Europe translates to one in 750 young adults being survivors of childhood cancer (Stiller et al. 
2006). 
Successful treatment of childhood cancers is achieved through multimodal approaches 
involving combination chemotherapy, radiotherapy and surgery. With exception of surgery, 
these treatments can adversely impact reproductive organs (Metzger et al. 2013). Ovaries are 
at risk to cancer treatment because of the finite numbers of non-renewable germ cells (Wo and 
Viswanathan 2009).  
Figure 4. Estimated New Cases of Childhood Cancers United States, 2014. 
Malignant cancers are onlyestimates and additionally 730 children will be diagnosed with benign 
andborderline brain tumors in 2014. *Includes ganglioneuroblastoma. †Bone tumors include 
osteosarcoma and Ewing sarcoma. Modified (Ward et al. 2014). 
Introduction                  12 
3. Chemotherapy drugs
Chemotherapy drugs are cytotoxic agents that used at their maximum tolerated dose (MTD) 
on the basis that this results in a large damage on cancer cells (Kummar et al. 2006). Cancer 
patients are treated dependently on each disease by combination chemotherapy protocols 
including chemotherapy agents, doses and duration of treatment (Meirow 2000). There are 
many different chemotherapy agents that are commonly used in the treatment of childhood 
cancer (Bickert 2002). For the present work, four different categories of chemotherapy agents 
(doxorubicin, vincristine, methotrexate and cyclophosphamide) have been chosen whose 
mechanisms of action and gonadotoxic potential are different. 
3.1. Doxorubicin 
Doxorubicin is an anthracycline antibiotic and one of the most commonly used 
chemotherapeutic drugs. It has been used to treat breast cancer, childhood solid tumors, 
leukemia and soft tissue sarcomas since the 1960’s (Minotti et al. 2004). As it plays a key role 
in the treatment of many types of cancer, its toxicity on noncancerous cells in the human body 
has been widely investigated. There is evidence that doxorubicin can cause damage in healthy 
tissue in brain, heart, liver and kidney by induction of apoptosis and necrosis (Tacar et al. 
2013). 
The mechanism of doxorubicin in cancer cells includes many different actions (Gewirtz 
1999). Doxorubicin enters the cell via passive diffusion and it can intercalate the base pairs of 
the DNA’s double helix, with inhibition of both DNA and RNA polymerase, eventually 
stopping DNA replication and RNA transcription. The major action of doxorubicin is 
inhibition of DNA associated enzymes such as topoisomerase enzymes I and II, which are the 
main targets of doxorubicin, resulting in DNA damage by induction of programmed cell death 
(Tacar et al. 2013). Topoisomerases  I are enzymes that cut the phosphate backbone one of the 
two strands of double-stranded DNA, while topoisomerase II cut both strands of the DNA 
helix and both allow for the unwinding of DNA (Press et al. 2011). Generation of free radicals 
is another action of doxorubicin which leads to DNA damage, inhibition of macromolecule 
production, DNA unwinding and an increase in alkylation (Gewirtz 1999, Minotti et al. 2004). 
The risk of doxorubicin on fertility has been categorized as medium (Wallace et al. 2005). 
After treatment with doxorubicin-containing protocols, the risk of amenorrhea ranges from 
20% to 80% and is dependent on the women’s age (Knobf 2006, Lee et al. 2006, Ben-Aharon 
et al. 2010). In an early study, amenorrhea was reported by 80% of premenopausal women 
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treated with chemotherapy regimens containing doxorubicin and most women over 40 years 
of age had irreversible amenorrhea, while 50% of women under 40 years of age had reversible 
amenorrhea (Hortobagyi et al. 1986). 
3.2. Vincristine 
Vincristine is an antimicrotubule agent, belonging to the class of Vinca alkaloids and cell 
cycle–specific cytotoxic drug. It was first isolated in 1961 (Raviña 2011) and used as a 
therapy for various cancers including breast cancer, Hodgkin’s disease, multiple myeloma, 
and lung  cancer. Vincristine is effective in the treatment of acute lymphoblastic leukemia 
(Ong et al. 2008). 
Vincristine’s mode of action as microtubule-targeted drug is suppression of microtubule 
dynamics by binding to the β subunit of the αβ–tubulin heterodimer and thereby disrupting 
microtubule structures of the cell cytoskeleton and mitotic spindle. Microtubules are major 
structural components of the cytoskeleton and play a key role in mitosis and are the target of a 
large and diverse group of anticancer drugs. Destabilization of microtubules by vincristine 
leads to mitotic block at the metaphase and apoptosis (Jordan 2002, Jordan and Wilson 2004). 
The risk of vincristine on fertility has been categorized as low (Wallace et al. 2005). 
Vincristine is usually applied in combination treatment with other cytostatic drugs. In 
treatment of Hodgkin's disease, a combination of vincristine, cyclophosphamide, procarbazine 
hydrochloride and prednisone, given in six cycles for 6 months, increased the response rate 
and survival of patients (Devita et al. 1970). The ovarian samples from patients who received 
alkylating regimen CHOP (vincristine, cyclophosphamide, doxorubicin and prednisone) had a 
decrease in primordial follicle counts and diminished follicle density when compared with 
untreated controls (Oktem and Oktay 2007a). 
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3.3. Methotrexate 
Methotrexate is an antimetabolite and was first identified as an anti-tumour agent in the 1947 
and being less toxic than other available agents (Sneader 2005). It is a powerful agent in 
treatment of acute lymphoblastic leukemia and it also used to treat choriocarcinoma, 
lymphoma (Bertino 1993), breast cancer (Tanabe 2016) and as well as rheumatoid arthritis 
(Lopez-Olivo et al. 2014, Kivitz et al. 2016) and ectopic pregnancy (Guth et al. 2011), either 
alone or in combination with other agents. As an antifolate methotrexate reduces the folic acid 
concentration thus leading to decreased leukemia cell populations in the blood (Bertino 1993). 
On the other hand, methotrexate can cause clinical neurotoxicity and asymptomatic 
leukoencephalopathy in children (Bhojwani et al. 2014). 
Mechanism of action of methotrexate in cancer cells is competitive inhibition of dihydrofolate 
reductase (DHFR), which is an enzyme that reduces dihydrofolic acid to tetrahydrofolic acid 
in presence of nicotinamide adenine dinucleotide phosphate (NADPH) as electron donor. 
Tetrahydrofolate is essential for the biosynthesis of thymidylate, de novo purine biosynthesis 
and several amino acid metabolisms. Because of its metabolic importance, DHFR has been a 
target for methotrexate. Therefore, inhibition folic acid that is required in nucleotides 
biosynthesis leads to inhibition of DNA, RNA and proteins production and eventually 
resulting in cell death (Fig. 5) (Rajagopalan et al. 2002). 
Estimated  risk of gonadal dysfunction with methotrexate is low risk (Wallace et al. 2005) 
and some studies reported no effect on fertility in women treated with methotrexate for 
ectopic pregnancy (Oriol et al. 2008, Uyar et al. 2013). In contrast, another study observed 
reduced endometrial glands and ovarian follicles in uteri and ovaries of mice treated with 
methotrexate for 6 months (Chelab and Majeed 2009). 
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   Figure 5. Methotrexate mechanism of action 
Methotrexate enters the cell through the reduced folate carrier using an endocytic pathway 
activated by a folate receptor. After entering the cell, methotrexate inhibits the enzyme 
dihydrofolate reductase, thus blocking the conversion of dihydrofolate to tetrahydrofolate. As 
result, thymidine and purine biosynthesis is reduced, this ultimately inhibits DNA and RNA 
synthesis. Modified (Skubisz and Tong 2012) 
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3.4.  Cyclophosphamide 
Cyclophosphamide is an alkylating agent and is one of the most successful and widely 
utilized anticancer drugs. It was approved for clinical use as chemotherapeutic agent in 1959. 
It is commonly used for treatment of a wide range of hematological malignancies, solid 
tumors and autoimmune diseases such as systemic lupus erythematsous. Furthermore, it is 
commonly used in blood and marrow transplantation as an effective immunosuppressive 
agent (Emadi et al. 2009). 
Cyclophosphamide is an inactive pro-drug and has to be activated by hepatic cytochrome P-
450 enzymes, while its active form 4-hydroperoxy-cyclophosphamide does not require 
hepatic activation (Teicher et al. 1996). Although toxicity of cyclophosphamide is not cell-
cycle specific, it is a cytotoxic agent for proliferating cells such as granulosa cells which are 
particular targets of action of cyclophosphamide (Plowchalk and Mattison 1992). 
The mechanism behind cyclophosphamide-induced follicle loss is activation of primordial 
follicle by up-regulation of the phosphatidylinositol 3-kinase (PI3K/PTEN/Akt) signaling 
pathway and causing growing follicles to undergo apoptosis, in this manner reducing of 
secretion of inhibitory factors. At the end, cyclophosphamide causing burn out and depletion 
of the ovarian reservoir, because increase of activation primordial follicles which are recruited 
into growth, develop and die (Fig. 6). In absence this disturbance in balance caused by 
cyclophosphamide, the ovary is in a state of equilibrium during normal follicular growth and 
the primordial follicles are under regulation of PI3K/PTEN/Akt pathway with action of 
suppressive factors (Kalich-Philosoph et al. 2013). 
Cyclophosphamide has extremely damaging effects on the ovary and carries highest risk of 
gonadal dysfunction (Meirow et al. 1999, Wallace et al. 2005). One single dose of 
cyclophosphamide caused loss of primordial follicles and follicles of all stage in ovaries of 
mice (Kalich-Philosoph et al. 2013). In another study on mice, cyclophosphamide treatment 
caused reduction in ovarian volume, destruction of antral follicle and low production of 
estradiol (Plowchalk and Mattison 1992). Similar results showed a reduction in ovarian 
weight in rats treated with cyclophosphamide (Sato et al. 2009). 
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Figure 6. Induction of follicle loss by cyclophosphamide 
(A) The PI3K/PTEN/Akt pathway and suppressive factors produced by growing follicles maintain a 
state of equilibrium during normal follicular development. (B) Treatment with cyclophosphamide 
causes imbalance and up-regulation of the PI3K/PTEN/Akt follicle activation pathway and causes 
apoptosis of growing follicles. At the end, burn out occurs in ovarian reservoir due to death of 
primordial follicles. Modified (Roness et al. 2014). 
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4. Chemotherapy and risk of infertility of female survivors of childhood cancer
After successful treatment, young female cancer survivors still have an elevated risk for late 
effects of chemotherapy treatments, such as a possible premature ovarian failure and 
infertility (Byrne et al. 1987, Byrne 1999, Sklar 2005, Green et al. 2009, Hamre et al. 2012, 
Thomas-Teinturier et al. 2013). A morphological study of the ovaries of leukemic children 
treated with cytotoxic agents demonstrated an inhibition in follicle development and a 
decrease of number and size of antral follicles in comparison to control group (Himelstein-
Braw et al. 1978). A structural study of the ovary in childhood leukemia after chemotherapy 
treatment showed a reduction in the number of follicles, absence of follicles in two 
postmenarcheal girls, moderate to severe signs of fibrosis in cortical stroma and changes in 
capillaries (Marcello et al. 1990). 
The Childhood Cancer Survivor Study followed a large number of patients diagnosed 
between 1970 and 1986 and found that female long-term survivors of childhood cancer were 
less likely to become pregnant compared to sibling controls (Green et al. 2009). Up to one 
third of adults who had been treated for cancer in childhood or in adolescence have suspected 
infertility in a large nationwide study of fertility in Germany (Balcerek et al. 2012). In a 
prospective cohort study on prepubertal and pubertal girls treated for cancer, AMH level was 
measured before, during and after each chemotherapy treatment. During chemotherapy, AMH 
was undetectable in 50% of patients and 100% of patients in the low/medium risk groups and 
high-risk group respectively. Hence, Anti-Müllerian Hormone is a useful and sensitive marker 
of ovarian reserve and gonadal function in women treated for cancer during childhood and 
can be detectable in girls of all ages (Brougham et al. 2012). 
Chemotherapy treatment in childhood that disrupts fertility in adulthood can have a shattering 
effect, both at the time of treatment and whenever the patient’s wishes to start family. Patients 
are in need to identify best options to minimize ovarian damage during chemotherapy. 
Therefore, the effect of chemotherapy is important to consider, as well as which strategies are 
available to protect fertility in later life. 
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5. Impact of chemotherapy on the ovary
The impact of chemotherapy on the ovary includes short and long-term effects depending on 
the severity of damage of primordial follicle population. During the treatment, damage of 
growing follicles leads to temporary amenorrhea which is an immediate effect of 
chemotherapy, while destruction of the primordial follicle pool leads to long-term effect. 
Permanent infertility can occur as result of the complete loss of primordial follicle reserve 
(Roness et al. 2014). 
Chemotherapy induces reduction of the primordial pool by two possible ways: direct killing 
of primordial follicles or indirect by damage of growing follicles which leads to the 
recruitment of more primordial follicles, both ways leading to premature ovarian failure (Fig. 
7 A) (Meirow et al. 2010). The various cell types in the ovary are potential targets of action of 
chemotherapeutic drugs. While non-dividing oocytes in the interior of the immature follicle 
may be a potential target for direct damage by cytostatic drugs via  initiation of cell death and 
subsequent loss of germ cells, mitotically- active granulosa cells are the preferably targets of 
chemotherapeutic agents (Fig. 7 B). Direct damage of granulosa cells leads to indirect damage 
of oocyte and causes loss of germ cell (Morgan et al. 2012). 
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Figure 7. Several potential targets in the ovary for toxic actions of chemotherapy 
(A) Direct damage of the primordial follicle pool or indirect damage of growing follicle damage 
caused by action of chemotherapeutics agents. More of primordial follicles are recruited into growth 
and so loss of that reserve due to loss inhibitory action of growing follicles. (B) Chemotherapy could 
directly damage the oocyte or somatic cells, which will lead indirect damage to oocyte and loss of 
follicle loss. Modified (Morgan et al. 2012). 
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6. Effect chemotherapy on granulosa cells
Granulosa cells are mitotically and metabolically active cells and proliferate during follicle 
maturation. Therefore, they are the primary ovarian targets to action of chemotherapeutics 
agents. Any damage of granulosa cells will lead to indirect damage of oocytes and hidden 
effects on primordial follicles (Morgan et al. 2012). This damage occurs mainly by inducing 
apoptosis in granulosa cells (Himelstein-Braw et al. 1978, Marcello et al. 1990, Meirow et al. 
2010, Chatterjee et al. 2014, Yuksel et al. 2015). 
In response to cytostatic drugs causing DNA damage, cells attempt to activate DNA repair 
mechanisms by a complex cascade response and failure of this attempt results in apoptosis. 
Apoptosis as mechanism of programmed cell death results in characteristic cytomorphological 
changes including cell shrinkage, chromatin condensation, membrane blebbing and formation 
apoptotic bodies (Elmore 2007). Apoptosis of granulosa cells in growing follicles is mediated 
by a Fas antigen- specific death inducer called FasL transmembrane protein (Perez et al. 1999, 
Utsunomiya et al. 2008) 
In a previous study, treatment with doxorubicin caused apoptosis of granulosa cells and 
oocytes of human primordial follicles (Soleimani et al. 2011). Similar results by another study 
identified DNA damage in granulosa cells when ovaries from mice were treated with 
doxorubicin (Ben-Aharon et al. 2010). An increase in damaged granulosa cell nuclei was 
observed in vitro when human ovarian cortical slices from premenopausal women were 
treated with cyclophosphamide (Raz et al. 2002). Other previous studies investigated effects 
of cyclophosphamide and doxorubicin on granulosa cells (Table 1). 
Summarized, granulosa cell apoptosis is one of the most important factors affecting the 
oocyte quality and has been associated with oocyte maturation delay and consequently 
deficient embryo development and poor pregnancy outcome (Lee et al. 2001, Host et al. 
2002). 
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Table 1. Previous studies on effects of cyclophosphamide and doxorubicin on granulosa cells 
Chemotherapy 
 regimen 
Author Model species   Target cells 
Cyclophosphamide (Ataya et al. 1990) Human 
Rat 
Granulosa cells 
(Tsai-Turton et al. 2007) Human granulosa 
cell lines 
COV434 
(Zhao et al. 2010) Rat Granulosa cells 
(Bildik et al. 2015) Human 
Human granulosa 
cell lines 
Granulosa cells 
COV434, HGrCl 
and HLGC 
(Yuksel et al. 2015) Human 
Human granulosa  
cell lines 
Rat granulosa cell lines 
Granulosa cells 
COV434, HGrCl 
and SIGC 
Doxorubicin (Soleimani et al. 2011) Human Granulosa cells 
(Sanchez et al. 2013) Human Granulosa cells 
(Turgeman et al. 2014) Human Granulosa cells 
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7. Chemotherapy and Premature Ovarian Failure
Premature Ovarian Failure means development of amenorrhoea due to premature depletion of 
functional ovarian follicle which leads to amenorrhea before age 40 (Goswami und Conway 
2005). The efficacy of chemotherapy on ovarian function depends on patient’s age, 
chemotherapeutic protocol and dose of drug administered (Meirow et al. 2010, Ben-Aharon 
und Shalgi 2012). 
The chemotherapeutic agents can be categorized according to their ovarian failure risk into 
three groups: high, medium and low risk (Wallace et al. 2005, Blumenfeld 2012). Alkylating 
agents possess the highest risk in causing ovarian failure. (Meirow 2000) found that risk of 
ovarian failure in patients treated with alkylating agents was 4.52 fold higher than in patients 
who were not treated with these drugs, while clinical studies found no risk of ovarian failure 
in patients treated with Vinca alkaloids (Meirow 2000, Lee et al. 2006). 
Moreover, treatment with doxorubicin and cyclophosphamide caused amenorrhea in 84% of 
treated women, but about half of them recovered the menstrual bleeding during nine months 
after treatment (Petrek et al. 2006). A cohort study of childhood cancer survivors who 
received chemotherapy including alkylating agents showed that, of the six female survivors, 
one developed premature ovarian insufficiency (Larsen et al. 2003). 
Risk of developing premature ovarian failure and infertility following chemotherapy has 
associated risks including cardiovascular disease and psychosocial problems, such as 
depression (Carter et al. 2005, Jeanes et al. 2007). 
The end result of the chemotherapy-induced damage to dividing cells of the ovary, granulosa 
cells, as well as to the oocyte, is premature ovarian failure leading to premature menopause 
and permanent infertility. 
Introduction                 24 
8. MicroRNAs: small molecules with important functions in reproduction
Recently, a large family of short, noncoding RNA molecules known as microRNAs 
(miRNAs) has begun to be explored in ovarian cells because of their critical regulatory role 
(Imbar und Eisenberg 2014). miRNAs have been identified more than 20 years ago as key 
posttranscriptional regulator of gene expression (Lee et al. 1993). They are approximately 21 
nucleotides long and represent approximately 1–3% of genes in humans and may regulate up 
to 90% of all genes (Silveri et al. 2006, Stefani and Slack 2006). miRNAs have a critical role 
in regulation of reproductive functions, especially in steroid synthesis, folliculogenesis, 
oocyte maturation, implantation and early embryonic development, differentiation and 
apoptosis (Sirotkin et al. 2009, Hossain et al. 2009, Donadeu et al. 2012). The authors 
suggested that miRNAs can control reproductive functions by enhanced or inhibited release of 
ovarian progestagen, androgen and estrogen in human granulosa cells and suggested that such 
miRNA-mediated effects may be potentially used for the regulation of reproductive processes 
including fertility and for the treatment of reproductive and other steroid dependent disorders 
of women (Sirotkin et al. 2009, Sang et al. 2013, Diez-Fraile et al. 2014). 
Nearly 2865 mature miRNAs have been identified in the human genome until now (Virant-
Klun et al. 2016) and the miRNA database miRBase is rapidly expanding with hundreds of 
new miRNA sequences added with every update. Therefore, in recent years, miRNAs have 
become a major focus of research in molecular biology. The first study on miRNA profiles in 
human mature oocytes and surrounding cumulus granulsoa cells identified three miRNAs 
abundant in oocytes (miR-184, miR-100 and miR-10A). They differed from the miRNAs 
abundant in cumulus cells in the ovarian follicle (Assou et al. 2013). Other studies analysed 
the miRNA profile in human ovarian granulosa cells (Sirotkin et al. 2009, Sirotkin et al. 2010, 
Tong et al. 2014, Xu et al. 2015) in human follicular fluid and mural granuloa cells (Moreno 
et al. 2015), in human granulosa cells tumor cell lines KGN and COV434 (Rosario et al. 
2013) and in ovarian cells of different species like mouse (Fiedler et al. 2008, Ahn et al. 
2010), cow (Hossain et al. 2009), pig (Zhou et al. 2015), sheep (McBride et al. 2012) and 
horse (Schauer et al. 2013). The stability of miRNAs in body fluids is a property that enables 
them to be used as novel biomarkers for detection of several human physiologic and 
pathologic processes, as described for follicular fluid of women with PCOS (Sang et al. 2013, 
Xu et al. 2015, Jiang et al. 2015). 
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8.1. Importance of miR-21 and miR-132 in granulosa cells 
miR-21 and miR-132 are among the most abundantly expressed miRNAs in human oocytes 
and granulosa cells (Assou et al. 2013, Velthut-Meikas et al. 2013). In human follicular fluid 
(Sang et al. 2013) and in mouse granulosa cells, they have been demonstrated to be 
upregulated after LH and human chorionic gonadotropin induction (Fiedler et al. 2008). 
Because miR-21 is an oncogenic miRNA playing a critical role in maintaining the survival of 
granulosa cells in periovulatory follicles and acting as an antiapoptotic factor in granulosa 
cells (Donadeu et al. 2012), it is a particularly interesting target of study.  
In miR-21-depleted mice apoptosis is significantly increased in ovaries in vivo in combination 
with transient increase in phosphatase and tensin homolog protein (PTEN) levels in granulosa 
cells (Carter et al. 2005, Fiedler et al. 2008, Hennebold 2010). In several studies, miR-132 has 
been demonstrated to be upregulated in rat granulosa cells by either cAMP (Hu et al. 2013) or 
FSH treatment. Xu et al. (2015) identified the role of miR-132 in estradiol synthesis in mouse 
granulosa cells (Xu et al. 2015). Their mimics increased estradiol secretion and their 
inhibitors decreased estradiol secretion. The mechanisms by which miR-132 regulates 
estradiol secretion remain unknown and are worthy of investigation in the future (Sang et al. 
2013). 
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CHAPTER 2 OBJECTIVE 
• To determine the potential association of different chemotherapeutic agents as part of
childhood cancer treatment with infertility in adults who survived pediatric cancer.
• To compare the effects of doxorubicin, vincristine, methotrexate and cyclophosphamide
on a human leukemia T cell line, granulosa cell lines and primary granulosa cells.
• To explore effects of chemotherapeutic agents on expression of miR-21 and miR-132 in a
primary granulosa cells, granulosa cell lines and a human leukemia T cell line.
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2.1 Experimental Design 
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CHAPTER 3 MATERIALS AND METHODS 
3.1. Chemicals and reagents 
Doxorubicin, vincristine, and methotrexate were gifts from the Pharmacy of the University 
Hospital Jena. All drugs were diluted in medium to obtain the different concentrations. 
Chemotherapy drugs were administered at their therapeutic blood concentrations. 
3.1.1. Active metabolite of cyclophosphamide: 4-hydroperoxy-cyclophosphamide 
Our preliminary experiments with 1 to 500µg/ml cyclophosphamide for 12-48 h did not 
increase apoptosis in cell lines as referred by non-significant decrease in cell viability at the 
highest dose, suggesting that these cells do not efficiently metabolize cyclophosphamide to its 
active metabolites. Therefore, the active metabolite of cyclophosphamide (4-hydroperoxy-
cyclophosphamide) was used for the subsequent experiments. The active metabolite of 
cyclophosphamide was a kind gift from Baxter Oncology (Halle/Westfalen, Germany) as 
powder of 20 mg and it has been divided to aliquots and stored at -20°C. 
3.2. Ethical aspects 
Informed consent was obtained from each couple for the use of the follicular fluid sample that 
was obtained during oocyte retrieval for the in vitro fertilization (IVF) or intracytoplasmic 
sperm injection (ICSI) treatment. This study was covered by a previous approval of local 
ethics committee at the Friedrich-Schiller University Jena.  
3.3. Cell culture 
Two cell lines, COV434, derived from a human granulosa cell tumor (Zhang et al.2000), and 
KGN, derived from steroidogenic human ovarian granulosa-like tumor cells (Nishi et al 
2001), were cultured in cell culture medium Dulbecco’s modified Eagle’s medium 
(DMEM)/Ham's F12; (Life Technologies,Inc., Grand Island, NY) and supplemented with 
10% fetal bovine serum (FBS) (Sigma Aldrich, Steinheim, Germany), and 1% 
penicillin/streptomycin (Life Technologies, Grand Island, New York, USA). The human 
leukemia T cell line Jurkat was maintained in RPMI 1640 (Life Technologies) and 
supplemented with 10% FBS and 1% penicillin/streptomycin. All cells were grown under 
standard conditions (37°C, 5% CO2, humidified tissue culture incubator). 
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Furthermore, mycoplasma contamination of all cell lines was excluded by using mycoplasma 
kits (INtRON biotechnology Inc. Sungnam, Korea) every six months. 
Table 2. Characterization and origin of cell lines 
Cell line Characterization Culture 
properties 
Source Reference 
COV434 Immortalized 
human granulosa 
cells 
(primary tumor) 
Adherent Health Protection 
Agency Culture 
Collection via 
Sigma-Aldrich 
(Zhang et al. 
2000) 
KGN Granulosa tumor 
cell 
Adherent Dr. Jana Ernstat 
the 
Halle University 
Hospital, 
Germany 
(Nishi et al. 
2001) 
Jurkat Immortalized 
human leukemia T 
cell 
Suspension Dr. John Hansen 
at the Fred 
Hutchinson 
Cancer Research 
Center, Seattle, 
USA 
(Abraham und 
Weiss 2004) 
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Figure 8. Human primary cells and cell lines used for this thesis 
Human primary granulosa cells (PGCs). Human granulosa cell lines COV434 and KGN (adherent cell 
lines). Human leukemia T cell line Jurkat (suspension cell line). 
KGN 
COV434 
Jurkat 
PGCs 
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3.4. Isolation of human primary granulosa cells and culture 
Ovarian follicular fluids (FF) were obtained from women undergoing infertility treatment 
with (IVF) or (ICSI) at the Reproductive Medicine Center in Jena. There was no information 
about the patients, stimulation protocol, medical treatments, or number of aspirated follicles, 
because of data protection. Importantly, FF from all aspirated follicles of each patient was 
pooled. In some cases, FF from two patients or the isolated granulosa cells from several 
patients were pooled to obtain sufficient numbers of granulosa cells. The protocol for 
isolation was established in previous studies in our Placenta Laboratory. In brief, primary 
granulosa cells were collected from the FF aspirates and were centrifuged initially for 5 min at 
700 × g, followed by layering them onto a 33% Percoll gradient (GE Healthcare Life 
Science), followed by a centrifugation for 20 min at 400 × g. Thereafter, 3 layers can be 
distinguished: a top layer containing the follicular fluid, a bottom layer containing 
erythrocytes, and a middle ring-like layer containing granulosa cells. This middle layer was 
collected, washed, resuspended in DMEM (Life Technologies) with 10% FBS(Sigma 
Aldrich) and 0.05% gentamycin (Life Technologies) and cultured at 37°C and 5% CO2 for 48 
hours to recover from effects of the in vivo exposure to gonadotropins. Cell suspensions were 
washed daily with phosphatase buffered saline (PBS) and medium was changed to remove the 
contaminating leukocytes, that do not adhere to the culture flask, whereas granulosa cells 
adhere, thus allowing easy segregation of the two cell types (Ferrero et al. 2012). 
3.5. Cell viability assay (MTS) 
Primary granulosa cells were cultured for 72 h and seeded in a 96-well cell culture plate at a 
density of 2×104 cells/well in triplicates. After further 24 h, the media was changed and 
different doses of doxorubicin (0.01, 0.05, 0.1, 0.2, and 0.5 μg/ml), vincristine (0.01, 0.1, 1, 5, 
and 10 μg/ml), methotrexate (0.1, 1, 5, 10, and 50 μg/ml) orcyclophosphamide (1, 5,10, 50 
and 100 μg/ml) were added and cells were incubated for further 48 h. The granulosa cell lines 
(KGN and COV434) and the leukemia T cell line Jurkat were treated for 12, 24 and 48 h with 
the same doses of doxorubicin, vincristine, methotrexate or cyclophosphamide. The cells 
incubated with medium only served as a control. Subsequently, cell viability was determined 
using a colorimetric methyl tetra-zolium salt (MTS)3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4sulfophenyl)-2H tetrazolium) Cell Titer 96 Aqueous One 
Solution cell proliferation assay (Promega, USA). 20 µl of MTS solution were added to each 
well, followed by incubation for 4 h. Absorbance was read at 490 nm on a Spectro star Omega 
microtiter plate reader. The wells containing medium but no cells served as blank controls. 
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Viability of test samples was determined as: % viability= (average OD for test group/average 
OD for control group) ×100. The values were obtained from at least three independent 
experiments (three wells each). 
3.6. Apoptosis (Annexin V assay) 
Apoptosis assessment was measured using a FITC conjugated annexin V and Propidium 
Iodide (PI) apoptosis kit (Miltenyi Biotechnology, Germany) by flow cytometry. According to 
the manufacturers’ instructions, cells were seeded in 6 well plates at a density of 5x105 
cells/well with 2 ml growth medium for 24 h to reach adherence and confluence, followed by 
incubation of cells with the first concentration which inhibited cell viability > 50% of either 
doxorubicin, vincristine, methotrexate or cyclophosphamidefor further 48 h. Adherent and 
floating cells were collected and then washed and resuspended in 1x binding buffer, followed 
by adding 100µl of buffer and 10µl of annexine V-FITC solution (which binds extracellularly 
to apoptotic cells) and cells were incubated in dark at room temperature for 15 min. Cells 
were washed with binding buffer and suspended in 500 µl of binding buffer and 5µl of 
Propidium iodide (which stains necrotic cells)  were added to cell suspension and followed by 
flow cytometer (BD FACSCalibur) and data analyzed by CellQuest Pro Program 
(BecktonDickinson, Mountain View, California). Apoptotic cells were Annexin V-FITC 
positive and necrotic cells were PI positive. 
3.7. RNA Isolation 
Primary granulosa cells, KGN, COV434 and Jurkat were seeded in 6-well plates at a density 
of 5×105 cells/well for 24 h, followed by treatment with 1μg/ml doxorubicin or vincristine or 
methotrexate or cyclophosphamide for further 24 h. Total cellular RNA was extracted from 
cultured cells using TRIZOL reagent according to the manufacturer´s instructions (Invitrogen, 
Darmstadt, Germany). Total RNA concentration was determined with a NanoDrop ND-1000 
spectrophotometer (PeqLab Biotechnologies GmbH, Erlangen, Germany). Samples with 
purity ratio more than 1.8 at A260/A280 were stored at -80°C until being processed.  
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3.8. Reverse transcription 
cDNA (complementary deoxyribonucleic acid) was synthesised using the Taqman microRNA 
reverse transcription kit (Applied Biosystems,Darmstadt, Germany) according to 
manufacturer’s protocol. In brief, reverse transcription reactions were set up in a reaction 
volume of 15 μl by combining 7 ml of reverse transcription (RT) master mix, including 
deoxynucleotide triphosphates (dNTPs), RT buffer, MultiScribeRT and RNase inhibitor. 5 ml 
of 10 ng of total RNA was combined with 3 ml of reverse transcription primer specific for 
each miRNA. Reverse transcription reaction was performed using a thermocycler (Eppendorf, 
Germany).  
Table 3. Reverse transcription reaction program 
Step Temperature in°C. Time in minutes 
1 16 30 
2 42 30 
3 85 5 
4 4 - 
3.9. Quantitative real-time PCR 
Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using Taqman 
microRNA assay for (hsa-miR-21-5p, Assay ID: 000397; hsa-miR-132-3p, Assay ID: 
000457; RNU-43 Assay ID: 001006) and Taqman universal PCR master mix reagents 
(Applied Biosystems) according to manufacturer’s protocol. Briefly, 10 ml of TaqMan 2x 
Universal PCR master mix was combined with 7.67 ml of nuclease-free water, 1 ml of 20x 
TaqMan MicroRNA. All reactions were run in duplicates, including no-template controls in 
96-well plates on a 7300 Real-time PCRsystem (Applied Biosystems). Experiments were 
performed in triplicates. Expression of miR-21 and miR-132 was calculated using the 
2−ΔΔCtmethod by relative to the housekeeping small nucleolar RNA U48 (RNU48). ΔΔCt = 
(CtmiR-21/ miR-132− CtRNU48) treated group− (CtmiR-21/ miR-132 − CtRNU48) control group.  
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Table 4. Real-time PCR program 
Step Temperature °C. Time Number of Cycles 
Activation 95 10 min 1 
Denaturation 95 15s 
40 Annealing/ Extension 60 60s 
3.10. Hormone assay 
The level of estradiol was determined in supernatants of primary granulosa cell cultures after 
48 h incubation of cells with different doses of either doxorubicin (0.01, 0.05, 0.1, 0.2, and 0.5 
μg/ml), vincristine (0.01, 0.1, 1, 5, and 10 μg/ml),methotrexate (0.1, 1, 5, 10, and 50 μg/ml) or 
cyclophosphamide (1, 5,10, 50 and 100 μg/ml). The analyses have been done by using an 
immunoassay for the in vitro quantitative determination of estradiol (immunoassay analyzers, 
Roche Diagnostics, USA) by the Institute of Clinical Chemistry, University Hospital Jena. 
The lower detection limit for estradiol was 18.4 pmol/l. The experiments were repeated at 
least three times. 
3.11. Statistics 
Each experiment was repeated independently at least three times. Two-tailed Student’s t-test 
was performed for statistical comparisons between experimental groups and values were 
presented as mean ± standard deviation (SD). Statistical analyses for miR-21 and miR-132 
expression levels were assessed by ANOVA with Turkey multiple-comparison test (GraphPad 
Prism version 6.0). P values <0.05 were considered statistically significant. 
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4.4. Chemotherapeutic drugs promote apoptosis in cells 
To assess the cytotoxic effects of chemotherapeutic drugs on apoptosis and necrosis of the 
different analyzed cells, cells were untreated, treated with first concentration which inhibited 
cell viability > 50% of either doxorubicin, vincristine, methotrexate or cyclophosphamide for 
48 h and stained with annexin V and propodium iodide (PI) for flow cytometry. 
In Jurkat cells, in response to vincristine the extent of necrosis (47.24%) was much higher 
than of apoptosis (21.62%). The lowest concentration was < 0.01 µg/ml of vincristine, applied 
for 48 h (Fig. 18 A and B). The percentage of apoptotic and necrotic KGN cells treated with 
the same concentration was below 10% each (Fig. 20 A and B). 
The greatest magnitude of cytotoxicity appeared in primary granulosa cells treated with 
50μg/ml cyclophosphamide and 0.5 μg/ml doxorubicin. Both induced apoptosis in 
approximately 80% of cells (Fig 21A and B). In untreated primary granulosa cells, 
32,27±6,04% of cells were annexin V-positive/PI negative, and 14,71±3,8 % of cells were 
annexinV–PI double positive, because granulosa cells are non-mitotic cells which do not 
survive long time in culture. 
Treatment with methotrexate induced significantly higher rates of cell death in Jurkat cells in 
comparison to control cells (Fig. 18 A and B) while it had low effect in COV434 cells, (Fig. 
19 A and B), KGN cells (Fig. 20 A and B) and primary granulosa cells (Fig. 21 A and B). 
Doxorubicin induced apoptosis in KGN, while no evidence of apoptosis was observed after 
incubation of KGN cells with the other tested cytostatic drugs (Fig. 20).  
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4.5. Effect chemotherapeutic drugs on expression of microRNAs 
To explore the potential effect of the cytostatic drugs on expression of miR-21 and miR-132 
in primary granulosa cells and cell lines, cells were treated with (1 μg/ml) of doxorubicin, 
vincristine, methotrexate or cyclophosphamide for 24 h. Expression was detected by 
quantitative real time PCR (qRT- PCR) and calculated using the delta delta cycle threshold 
(ΔΔCt) method relative to the housekeeping small nucleolar RNA U48 (RNU48). 
4.5.1 Expression of miR-21 after treatment with cytostatic drugs 
Expression of miR-21 was significantly increased in COV434 cells that were treated with 
doxorubicin but not in KGN (Fig. 22A), primary granulosa cells or Jurkat cells (Fig. 22B), 
while treatment with vincristine, methotrexate or cyclophosphamide did not significantly 
change miR-21 expression (Fig. 22). 
4.5.2. Expression of miR-132 after treatment with cytostatic drugs 
In KGN cells treated with doxorubicin, the expression level of miR-132 was significantly 
increased (Fig 23A) whereas it was not significantly altered in COV434 cells (Fig 23B). 
Expression of miR-132 was also significantly increased in Jurkat cells that were treated with 
doxorubicin or vincristine (Fig. 23B). 
4.5.3. Effect of doxorubicin on expression of miR-21 and miR-132 in cells 
In order to determine whether the effect of doxorubicin on expression of miR-21 and miR-132 
in cells is dose-dependent, KGN and COV434 cells were untreated or treated with increasing 
doses (0.01, 0.05, 0.1, 0.2, and 0.5 μg/ml) of doxorubicin for 24 h.  
Expression of miR-21 in COV434 cells (Fig. 24A) and KGN cells (Fig.24 B) was not dose-
dependent. In contrast, in COV434 cells, the expression of miR-132 increased in a dose-
dependent manner (Fig.25A), but not in KGN cells (Fig.25B). 
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A 
B 
Figure 22. Expression of miR-21 in cells 
(A) Relative expression of miR-21 in KGN and COV434 cells, (B) primary granulosa cells (PGCs) 
and Jurkat cells which were untreated, treated with (1 μg/ml) of doxorubicin, vincristine, methotrexate 
or cyclophosphamide for 24 h. miR-21 expression was calculated using the 2−∆∆Ct method 
normalized to the housekeeping small nucleolar RNA U48 (RNU48). Data are represented as mean ± 
SE, n = 3 each in triplicates (ANOVA test). 
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A 
B 
Figure 23. Expression of miR-132 in cells 
(A) Relative expression of miR-132 in KGN and COV434 cells, (B) primary granulosa cells (PGCs) 
and Jurkat cells, which were untreated, treated with (1 μg/ml) of doxorubicin, vincristine, methotrexate 
or cyclophosphamide for 24 h. miR-132 expression was calculated using the 2−∆∆Ct method 
normalized to the housekeeping small nucleolar RNA U48 (RNU48). Data are represented as mean ± 
SE, n = 3 each in triplicates. *p < 0.05 (ANOVA test). 
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A 
B 
Figure 24. Effect of doxorubicin on expression of miR-21 in cells 
Relative expression of miR-21 in (A) KGN cells and (B) COV434 cells were untreated, treated with 
increasing doses of doxorubicin (0.01, 0.05, 0.1, 0.2, and 0.5 μg/ml) for 24h. miR-21 expression was 
calculated using the 2−∆∆Ct method normalized to the housekeeping small nucleolar RNA U48 
(RNU48). Data are represented as mean ± SE, n = 3 each in triplicates (ANOVA test). 
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A 
B 
Figure 25. Effect of doxorubicin on expression of miR-132 in cells 
Relative expression of miR-132 in (A) KGN cells and (B) COV434 cells were untreated, treated with 
increasing doses of doxorubicin (0.01, 0.05, 0.1, 0.2, and 0.5 μg/ml) for 24 h. miR-132 expression was 
calculated using the 2−∆∆Ct method normalized to the housekeeping small nucleolar RNA U48 
(RNU48). Data are represented as mean ± SE, n = 3 each in triplicates (ANOVA test). 
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CHAPTER 5 DISCUSSION 
Childhood cancer is one of the leading causes of death by disease among children in the world 
and the number of reported new cancer cases is increasing every year. Acute lymphoblastic 
leukemia is the most common malignancy in childhood, accounting for 26% of pediatric cancer 
diagnoses (Ward et al. 2014). Aim of childhood cancer treatment is to improve the long term 
survival rates and maintain healthy life. It has been reported that improvement of childhood 
cancer treatment has resulted in a 5-year survival rate exceeding 80% (Keegan et al. 2016). 
Infertility and premature ovarian failure are potential reproductive consequences of exposure to 
cytotoxic chemotherapy regimens in young females with cancer. The risk of developing 
premature ovarian failure following chemotherapy has associated risks including 
cardiovascular disease and psychosocial problems, such as depression (Carter et al. 2005, 
Jeanes et al. 2007).  The rate of infertility in general population is around 5% (Gnoth et al. 
2005), in 25 years old women 3% and  in 30 years old women 6% (Habbema et al. 2009). 
Interestingly, the rate of infertility is up to one third higher in survivors of childhood cancer 
depending on age of patients at treatment and the type of treatment (Balcerek et al. 2012). 
Therefore, the current strategy is focused on fertility improvement in childhood cancer 
survivors. 
Combination chemotherapy is an essential part of treatment for the majority of childhood 
cancers and leading to long term remission in childhood ALL (Jenkins 2013). Due to limited 
data available on the ovarian damage caused by individual chemotherapy agents, this study 
aimed to investigate the potential effect of different drugs on human ovarian granulosa cells. 
We selected four different categories of chemotherapy agents (doxorubicin, vincristine, 
methotrexate and cyclophosphamide) that are commonly used in treatment of childhood 
cancers with different mechanisms of action and gonadotoxic effect. 
The mechanisms of chemotherapeutic agents are not specifically targetting the tumor. They can 
exert their effects on the growth of many cell types with particular cytotoxicity to dividing 
cells. Granulosa cells are somatic cells within follicles with a high degree of proliferation, 
whereas oocytes rapidly develop in follicles, but do not divide. Granulosa cells have their 
central role in supporting oocyte growth and development as well as in the coordination of 
folliculogenesis in response to gonadotropin signaling and through their bidirectional 
communication with the oocyte and theca cells (Knight and Glister 2006). 
 Discussion           57 
Moreover, granulosa cells are also involved in production of estrogens via cytochrome P450 
aromatase, a key enzyme in estradiol biosynthesis (Albertini et al. 2001, Senthilkumaran et al. 
2004). Any impairment of granulosa cells and their ability to proliferate may also have an 
indirect effect on follicle development and may cause damage of the oocyte and consequently 
deficient embryo development and poor pregnancy outcome (Morgan et al. 2012). This fact 
opened the path to study the effect of chemotherapeutics drugs on human granulosa cells. 
Despite the inverse relationship between gonadotoxicity of chemotherapy and female age, 
chemotherapeutic destruction of follicles occurs at all ages (Meirow 2000). Reduction of the 
likelihood of pregnancy was associated with treatment of alkylating agents in a dose-dependent 
manner in female survivors from childhood cancer between 1970 – 1986 by Childhood Cancer 
Survivor Study (CCSS) (Green et al. 2009). 
There are no comparisons so far of effects of chemotherapeutic drugs on human leukemia T 
cell lines and human granulosa cells. Hence, in this study we have analysed and compared the 
effects of chemotherapeutic drugs on viability and apoptosis of normal primary granulosa cells, 
the granulosa cell lines KGN, COV434 and human leukemia T cell line Jurkat. 
The protocol used in this study allows the isolation of primary granulosa cells from follicular 
aspiration from patients undergoing IVF or ICSI. Follicular fluid contains mainly luteinizing 
granulosa cells. Red and white blood cells may be also present in this fluid, which may disturb 
further experiments if they are not completely removed (Quinn et al. 2006).  
Two granulosa cell lines were used in this study: the steroidogenic human ovarian granulosa 
cell line, KGN, which contains most physiological properties such as expression of FSH 
receptor and pattern of steroidogenesis similar to normal human granulosa cells (Nishi et al. 
2001), and the immortalized granulosa cell line COV434 that also expresses FSH receptor and 
produces estradiol through the action of cytochrome aromatase and possesses many of 
characteristics of normal luteinized granulosa cell (Zhang et al. 2000). KGN was isolated from 
a patient with invasive ovarian granulosa cell carcinoma (Nishi et al. 2001), while COV434 
was isolated from a 27 years old female patient with metastatic granulosa cell carcinoma 
(Vandenbergbakker et al. 1993).  
Our tested chemotherapeutic drugs are commonly used in treatment of acute lymphoblastic 
leukemia in children. Therefore, we used Jurkat cells, an acute T lymphoplastic leukemia cell 
line of human origin as a model for this study (Abraham and Weiss 2004). 
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The human risk of chemotherapeutic agents can be categorized according to their ovarian 
failure risk into three groups: high, medium and low risk (Wallace et al. 2005, Blumenfeld 
2012). The risk of impairment of ovarian function in patients treated with alkylating agents is a 
fourfold higher than in patients treated with other chemotherapy agents (Meirow und Nugent 
2001). Cyclophosphamide is an alkylating agent posing the highest risk for ovarian failure in a 
study more than 40 years ago (Warne et al. 1973). Our preliminary experiments with high 
concentrations of cyclophosphamide indicated that it was non-cytotoxic in vitro, because it is a 
pre-drug and requires to be converted to active form in liver (Teicher et al. 1996). Therefore, 
we decided to use the active metabolite of cyclophosphamide (4-hydroperoxy-
cyclophosphamide) which is similar to other studies (Tsai-Turton et al. 2007, Turgeman et al. 
2014, Yuksel et al. 2015). 
In this study, the cytotoxic effects of each treatment were evaluated by using a methyl 
tetrazolium salt (MTS) assay that shows the metabolic activity of cells. A slight reduction of 
cell viability was observed after 12 and 24 h of culture. Therefore, cells were treated for 48 h. 
Our results demonstrate that treatment with cyclophosphamide for 48 h caused a significant 
degree of cytotoxicity on all cell lines. The observed reduction in viability of primary granulosa 
cells by high concentrations of cyclophosphamide (50 and 100 μg/ml) was massive and in line 
with the observed reduction of estradiol production in cultures treated with same concentrations 
of this drug. This finding is similar with a result of a recent study (Bildik et al. 2015). Estradiol 
has been shown to play an important role in follicle development and ovulation.  
Staining with fluorescein-conjugated Annexin V and PI demonstrated the percentage of 
apoptotic and necrotic cells in our study. We found that 50 μg/ml cyclophosphamide treatment 
induced primary granulosa cell apoptosis. Our result is in agreement with a recent study that 
reported cyclophosphamide induced apoptosis in human granulosa cells as well as in primordial 
and growing follicles in the rat ovary (Yuksel et al. 2015). Another study showed that 
cyclophosphamide decreased functions of human granulosa cell line COV434 in vitro and 
initiation of apoptosis by inducing oxidative stress mediated by glutathione depletion (Tsai-
Turton et al. 2007). Gonadal toxicity with cyclophosphamide alone or in combination with 
other chemotherapeutic drugs has been documented. The authors found that in women treated 
with cyclophosphamide and doxorubicin, 84% became amenorrhoeic by the end of treatment 
(Petrek et al. 2006) and previous studies confirmed that cyclophosphamide has an extremely 
damaging effect on the ovary (Ataya et al. 1990, Meirow et al. 1999). Primordial follicles were 
decreased in mice treated with cyclophosphamide in a dose dependent manner (Meirow et al. 
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1999). Moreover, a single dose of cyclophosphamide induced a severe reduction in human 
primordial reserve in a xenograft model (Oktem and Oktay 2007b).  
Doxorubicin, an anthracyclin antibiotic, causes cell death through intercalation with genomic 
DNA, inhibition of topoisomerase enzymes, DNA replication and cell division (Jurisicova et al. 
2006). It is an essential drug in treatment for many different childhood cancers (Essig et al. 
2014). However, risk of doxorubicin on fertility has been categorized as medium (Wallace et 
al. 2005). It has been linked to premature ovarian failure by inducing ovarian damage and 
follicle loss (Ben-Aharon et al. 2010, Morgan et al. 2012). As observed in previous studies, in 
human primordial follicles both the granulosa cells and oocyte were impaired after doxorubicin 
treatment in vitro (Soleimani et al. 2011, Morgan et al. 2012). In our study we found that there 
was a significant decrease in viability of all tested cells after treatment with doxorubicin in 
dose-dependent manner. At the highest dose of doxorubicin (0.5 μg/ml), the percentage of 
apoptotic cells was 80%. Estradiol expression gradually declined simultaneously along with 
increasing concentrations of this drug in primary granulosa cell cultures. This finding is 
consistent with previous reports that doxorubicin affects granulosa cell viability and induces 
apoptosis (Ben-Aharon et al. 2010, Morgan et al. 2012, Roti et al. 2012, Sanchez et al. 2013, 
Turgeman et al. 2014). Granulosa cells are mitotically active and their sensitivity to 
doxorubicin may be related to the fact that doxorubicin interferes with cellular replication and 
transcription. Therefore, granulosa cells are the main ovarian target of cell damage by 
doxorubicin which causes indirectly germ cell death, and hence, follicle loss.  
To date, in general, the evidence suggests that the dosage of the chemotherapy treatment is an 
important factor for induction of early menopause (Chiarelli et al. 1999). Our results revealed 
that cyclophosphamide and doxorubicin dose-dependently induced apoptosis in granulosa cells. 
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There are too limited data available on the effects of methotrexate on human granulosa cells in 
vitro. Methotrexate is an antimetabolite and an essential drug in the treatment of acute 
lymphoblastic leukemia in childhood (Essig et al. 2014). It acts specifically during the S-phase 
of the cell cycle, where it prevents the growth and proliferation of dividing cancer cells by 
inhibition of folic acid production, which is required for nucleotide biosynthesis (Rajagopalan 
et al. 2002). The estimated risk of gonadal dysfunction with methotrexate is low (Wallace et al. 
2005). Our results showed that methotrexate was highly effective in inhibiting Jurkat cells 
viability, whereas primary granulosa cells and cell lines were comparatively resistant to the 
cytotoxic effects of methotrexate at higher concentrations. Moreover, treatment of primary 
granulosa cells with different concentrations of methotrexate had no effect on estradiol level. 
Thus, this finding suggests that methotrexate may be useful as therapeutic agent in treatment of 
acute lymphoblastic leukemia with less cytotoxic effects on granulosa cells. Our findings are in 
line with previous studies reporting no effects of methotrexate on fertility in ectopic pregnant 
women (Oriol et al. 2008, Uyar et al. 2013). Moreover, it has been reported that addition of 
methotrexate to alkylating agent regimens was not associated with an increase in amenorrhea 
after treatment. Benian et al. (2013) investigated the effect of methotrexate on rat ovaries by 
measuring serum AMH, that is produced by granulosa cells in primary to small antral follicles 
of the adult ovary. There was no change in AMH levels in serum before and after treatment 
(Benian et al. 2013). In contrast, another study observed reduction of endometrial glands and 
ovarian follicles in uteri and ovaries of mice, which were treated with methotrexate for 6 
months (Chelab and Majeed 2009). In another study, treatment with methotrexate has been 
associated with early ovarian failure in childhood cancer survivors (Lantinga et al. 2006). 
To the best of our knowledge, there are no previous studies in literature on effects of vincristine 
on human granulosa cells and cell lines in vitro.Vincristine is an antimicrotubule agent, disrupts 
microtubule structures of the cell cytoskeleton and mitotic spindle which leads to mitotic block 
at the metaphase and apoptosis (Jordan 2002, Jordan and Wilson 2004). It is effective in the 
treatment of acute lymphoblastic leukemia (Ong et al. 2008). In our hands, vincristine had the 
highest cytotoxic effect on the viability of Jurkat cells and both granulosa cell lines (KGN and 
COV434), but there was no deleterious effect on the viability of primary granulosa cells. This 
finding may suggest that primary granulosa cells can respond differently to vincristine. One 
explanation for this difference in response to vincristine between malignant cells (KGN and 
COV434) and non-malignant cells (primary granulosa cells), is the proliferation capacity of the 
two cell types: cancer cells proliferate rapidly, whereas primary granulosa cells proliferate 
minimally or do not proliferate at all (Ferrero et al. 2012). 
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Interestingly, the percentage of apoptotic and necrotic cells following treatment with vincristine 
at the lowest concentration (0.01µg/ml) was markedly increased in Jurkat cells when compared 
to similar concentrations of this drug in the primary granulosa cells and cell lines, which may 
indicate that Jurkat cells are more susceptible to vincristine-induced cell death. Our results are 
in agreement with a previous study that vincristine induced cell death in Jurkat cells (Shen et al. 
2013). Vincristine, at low concentration, has been reported to be less gonadotoxic. Also our 
results demonstrated that it had lower toxicity on granulosa cells than cyclophosphamide and 
doxorubicin with regard to their estradiol production. 
Another interesting point is the high sensitivity of Jurkat cells to low doses of all tested 
chemotherapeutic drugs in our study. The dose-and time dependent cytotoxic effects on these 
cells are consistent with previous studies (daSilva et al. 1996, Friesen et al. 1996, Gamen et al. 
1997, Amit et al. 2009, Sabova et al. 2010). 
Development of drugs for protection of non-tumor cells or specific ovary protection may 
reduce chemotherapy side effects. Several studies have demonstrated potentially beneficial 
treatments (Imai et al. 2007, Morgan et al. 2012). The best way of protecting the ovary from 
chemotherapy-induced damage could be to directly and specifically prevent any damage 
caused.  
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microRNAs are short non-coding RNA molecules and consist of approximately 21 nucleotides 
and represent approximately 1–3% of genes in humans (Silveri et al. 2006). miRNAs regulate 
gene expression of hundreds of target mRNA post-transcriptionally by binding to the mRNA 
3’- untranslated region. miRNAs control physiological and pathological processes such as cell 
proliferation, cell differentiation, apoptosis and tumorigenesis (Lee and Dutta 2009). Recently, 
miRNAs have begun to be explored in ovary where they have a regulatory role in 
folliculogenesis, oocyte maturation, implantation and early embryonic development (Hossain et 
al. 2009, Sirotkin et al. 2009, Donadeu et al. 2012). 
It is well documented that miRNAs are expressed in human granulosa cells and follicular fluid. 
miR-21 and miR-132 are among the most abundantly expressed miRNAs in human oocytes and 
granulosa cells (Assou et al. 2013, Velthut-Meikas et al. 2013) as well as in human follicular 
fluid (Sang et al. 2013), suggesting their important roles in ovarian granulosa cell functions. 
Therefore, based on these findings and existing literature we aimed to investigate effects of 
chemotherapeutic drugs on miR-21 and miR-132 expression in different granulosa cell lines 
and primary granulosa cells as well as in Jurkat cells.  
Interestingly, our experiments revealed that doxorubicin led to overexpression of miR-21 in 
COV434 cells but not in KGN cells. By increasing the doxorubicin concentrations, expression 
of miR-132 in COV434 cells increased. Previous studies revealed that cell proliferation and 
chemoresistance to doxorubicin were promoted by overexpression of miR-21 in bladder cancer 
cells (Tao et al. 2011). A recent and functional study has demonstrated that overexpression of 
miR-21 enhanced cell proliferation, migration and invasion in trophoblast cells (Chaiwangyen 
et al. 2015).  In ovary, miR-21 has been identified as promoting follicular cell survival during 
ovulation (Donadeu et al. 2012). In Jurkat cells, the level of miR-132 expression increased 
significantly after treatment with 1 μg/ml doxorubicin and vincristine. In a previous study, a 
key role of miR-132 in promotion of estradiol synthesis in murine ovarian granulosa cells has 
been reported (Wu et al. 2015), but its role in human granulosa cells remains unknown. Thus, 
our future work will continue to elucidate functions of miR-132 in human granulosa cells and 
to assess its role in the regulation steroidogenesis in these cells. 
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CHAPTER 6 CONCLUSION 
Premature ovarian failure and infertility in adulthood are significant long-term effects of 
exposure to cytotoxic treatment during childhood. Type and dose of cytotoxic drugs 
determine the degree of ovarian damage resulting in reduced fertility. Our findings 
demonstrate that Jurkat cells have a high sensitivity to all chemotherapeutic agents tested in 
our study which induced dose-and time dependent cytotoxic effects. The results of our study 
indicate that treatment of primary granulosa cells with doxorubicin and cyclophosphamide 
results in a significant increase in cell death and a dose-dependent decrease in cell viability 
and estradiol production. In contrast, there is a comparatively low impact of methotrexate and 
vincristine on the viability and steroidogenesis of human primary granulosa cells.  
Overall, the primary granulosa cells and cell lines express miR-21 and miR-132 which play 
important roles in cell functions. We demonstrated that doxorubicin strongly enhances 
expression of miR-21 and miR-132 in granulosa cell lines. It may be argued that similar 
effects occur in vivo, but their potential influence on fertility cannot yet be estimated.  
The knowledge about the potential damaging effects of cytostatic drugs on human ovarian 
function should be considered in selection of treatment and in development of novel treatment 
regimens. More research on the cellular mechanisms behind chemotherapy-induced follicle 
loss may lead to the generation of treatments specifically designed to prevent premature 
ovarian failure and infertility.  
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